These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 20709109)
1. Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. Lai BE; Geonnotti AR; Desoto MG; Montefiori DC; Katz DF Antiviral Res; 2010 Nov; 88(2):143-51. PubMed ID: 20709109 [TBL] [Abstract][Full Text] [Related]
2. Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels. Lai BE; Henderson MH; Peters JJ; Walmer DK; Katz DF Biophys J; 2009 Nov; 97(9):2379-87. PubMed ID: 19883580 [TBL] [Abstract][Full Text] [Related]
4. Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand. Whitehead SJ; McLean C; Chaikummao S; Braunstein S; Utaivoravit W; van de Wijgert JH; Mock PA; Siraprapasiri T; Friedland BA; Kilmarx PH; Markowitz LE PLoS One; 2011; 6(9):e14831. PubMed ID: 21915249 [TBL] [Abstract][Full Text] [Related]
5. After microbicide failures, hope that antiviral approach will gel. Padma TV Nat Med; 2008 Apr; 14(4):354. PubMed ID: 18391925 [No Abstract] [Full Text] [Related]
6. Vaginal deployment and tenofovir delivery by microbicide gels. Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971 [TBL] [Abstract][Full Text] [Related]
7. Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. Richardson BA; Kelly C; Ramjee G; Fleming T; Makanani B; Roberts S; Musara P; Mkandawire N; Moench T; Coletti A; Soto-Torres L; Karim SA; J Acquir Immune Defic Syndr; 2013 May; 63(1):120-5. PubMed ID: 23334506 [TBL] [Abstract][Full Text] [Related]
8. The future of HIV microbicides: challenges and opportunities. Garg AB; Nuttall J; Romano J Antivir Chem Chemother; 2009; 19(4):143-50. PubMed ID: 19374141 [TBL] [Abstract][Full Text] [Related]
9. Dilution of microbicide gels with vaginal fluid and semen simulants: effect on rheological properties and coating flow. Lai BE; Xie YQ; Lavine ML; Szeri AJ; Owen DH; Katz DF J Pharm Sci; 2008 Feb; 97(2):1030-8. PubMed ID: 17724667 [TBL] [Abstract][Full Text] [Related]
10. Dynamics of HIV neutralization by a microbicide formulation layer: biophysical fundamentals and transport theory. Geonnotti AR; Katz DF Biophys J; 2006 Sep; 91(6):2121-30. PubMed ID: 16815899 [TBL] [Abstract][Full Text] [Related]
11. Prevention, Partners, and Power Imbalances: Women's Views on How Male Partners Affected Their Adherence to Vaginal Microbicide Gels During HIV Prevention Trials in Africa. Miller L; Morar N; Kapiga S; Ramjee G; Hayes R J Acquir Immune Defic Syndr; 2020 Dec; 85(4):458-465. PubMed ID: 33136745 [TBL] [Abstract][Full Text] [Related]
12. Vaginal microbicides: moving ahead after an unexpected setback. van de Wijgert JH; Shattock RJ AIDS; 2007 Nov; 21(18):2369-76. PubMed ID: 18025873 [No Abstract] [Full Text] [Related]
13. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. Forbes CJ; Lowry D; Geer L; Veazey RS; Shattock RJ; Klasse PJ; Mitchnick M; Goldman L; Doyle LA; Muldoon BC; Woolfson AD; Moore JP; Malcolm RK J Control Release; 2011 Dec; 156(2):161-9. PubMed ID: 21864598 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration. McBride JW; Dias N; Cameron D; Offord RE; Hartley O; Boyd P; Kett VL; Malcolm RK Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784672 [TBL] [Abstract][Full Text] [Related]
15. Reformulated tenofovir gel for use as a dual compartment microbicide. Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908 [TBL] [Abstract][Full Text] [Related]
16. Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing. Braunstein S; van de Wijgert J J Womens Health (Larchmt); 2005 Jun; 14(5):424-33. PubMed ID: 15989415 [TBL] [Abstract][Full Text] [Related]
17. Vaginal drug distribution modeling. Katz DF; Yuan A; Gao Y Adv Drug Deliv Rev; 2015 Sep; 92():2-13. PubMed ID: 25933938 [TBL] [Abstract][Full Text] [Related]
18. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. Neff CP; Kurisu T; Ndolo T; Fox K; Akkina R PLoS One; 2011; 6(6):e20209. PubMed ID: 21673796 [TBL] [Abstract][Full Text] [Related]
19. Twice-daily application of HIV microbicides alter the vaginal microbiota. Ravel J; Gajer P; Fu L; Mauck CK; Koenig SS; Sakamoto J; Motsinger-Reif AA; Doncel GF; Zeichner SL mBio; 2012 Dec; 3(6):. PubMed ID: 23249810 [TBL] [Abstract][Full Text] [Related]
20. Acceptability and feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides. Coetzee N; Blanchard K; Ellertson C; Hoosen AA; Friedland B AIDS; 2001 Sep; 15(14):1837-42. PubMed ID: 11579246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]